Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-Naïve patients prescribed efavirenz compared to atazanavir/ritonavir

HIV Clinical Trials

Volumn 13, Issue 5, 2012, Pages 245-255

  Gotti, Daria ^a   Cesana, Bruno Mario ^b   Albini, Laura ^a   Calabresi, Alessandra ^a   Izzo, Ilaria ^a   Focà, Emanuele ^a   Motta, Davide ^a   Bellagamba, Rita ^c   Fezza, Rita ^c   Narciso, Pasquale ^c   Sidhinolfi, Laura ^d   Maggi, Paolo ^e   Brianese, Nigritella ^a   Quiros Roldan, Eugenia ^a   Guaraldi, Giovanni ^f   Torti, Carlo ^a,g  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^e POLICLINICO   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

antiretroviral therapy; cardiovascular risk; human immunodeficiency virus; lipids; lipoproteins

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; CHOLESTEROL; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HIGH DENSITY LIPOPROTEIN BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPROTEIN BLOOD LEVEL; LOW DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 84868695746     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1305-245     Document Type: Article

References (35)

1. Law MG, Friis-Møller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med. 2006;7(4): 218-230.
2. Currier JS. Update on cardiovascular complications in HIV infection. Top HIV Med. 2009;17(3): 98-103.
3. Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretro-viral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17): 1723-1735. (Pubitemid 46658704)
4. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus rito-navir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7): 445-456.
5. Ganesan A, Benning L, Golub ET, et al. Serum lipid profi les among patients initiating ritonavir-boosted atazana-vir versus efavirenz-based regimens. AIDS Res Ther. 2009;6: 13.
6. Wilson PWF, Abbott RD, Castelli W P. High-density lipo-protein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 1988;8(6): 737-741. (Pubitemid 19005358)
7. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26(4): 847.
8. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95(8): 764-772. (Pubitemid 39390578)
9. van der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: Signifi cance for cardiovascular risk. The IDEAL and EPIC-Norfolk Studies. J Am Coll Cardiol. 2008;51(6): 634-642. (Pubitemid 351186873)
10. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol. 2010;21(4): 312-318.
11. Duprez DA, Kuller LH, Tracy R, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis. 2009;207(2): 524-529.
12. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profi les by nuclear magnetic resonance compared with standard lipids and apolipo-proteins in predicting incident cardiovascular disease in women. Circulation. 2009;119(7): 931-939.
13. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study. Arterio-scler Thromb Vasc Biol. 2002;22(7): 1175-1180. (Pubitemid 34764870)
14. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs high-density lipoprotein intervention trial. Circulation. 2006;113(12): 1556-1563. (Pubitemid 43739414)
15. Lyons TJ, Jenkins AJ, Zheng D, et al. Nuclear magnetic resonance-determined lipoprotein subclass profi le in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabet Med. 2006;23(9): 955-966. (Pubitemid 44257939)
16. Stein JH, Komarow L, Cotter BR, et al. Lipoprotein changes in HIV-infected antiretroviral-naive individuals after starting class-sparing antiretroviral therapy: ACTG Study A5152s. J Clin Lipidol. 2008;2(6): 464-471. (Pubitemid 352795714)
17. Albini L, Cesana BM, Motta D, et al. A randomized, pilot trial to evaluate glomerular fi ltration rate by creatinine or cystatin C in naïve HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defi c Syndr. 2012;59(1): 18-30.
18. European Medicines Agency (EMEA). ICH Topic E 6 (R1) Guideline for Good Clinical Practice. July 2002. http://www.emea.europa.eu/docs/en-GB/document- library/Scientifi c-guideline/2009/09/WC500002874.pdf.
19. Ballantyne CM, Hoogeveen RC. Role of lipid and lipopro-tein profi les in risk assessment and therapy. Am Heart J. 2003;146: 227-233. (Pubitemid 36951765)
20. McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 2005;96(3): 399-404. (Pubitemid 41058868)
21. Hanak V, Munoz J, Teague J, Stanley A, Bittner V. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein pheno-type B. Am J Cardiol. 2004;94(2): 219-222. (Pubitemid 38902877)
22. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) fi nal report. Circulation. 2002;106(25): 3143-3421.
23. Shlay JC, Bartsch G, Peng G et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defi c Syndr. 2007;44(5): 506-517. (Pubitemid 46594893)
24. Fontas E, van Leth F, Sabin CA et al. Lipid profiles in HIV-infected patients receiving combination antiretrovi-ral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189(6): 1056-1074. (Pubitemid 38373099)
25. Young J, Weber R, Rickenbach M et al. Lipid profiles for antiretroviral-naive patients starting PI-and NNRTI-based therapy in the Swiss HIV Cohort Study. Antivir Ther. 2005;10(5): 585-591. (Pubitemid 41224950)
26. Franssen R, Sankatsing RR, Hassink E, et al. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arte-rioscler Thromb Vasc Biol. 2009;29(9): 1336-1341.
27. Podzamczer D, Andrade-Villanueva J, et al. Lipid profi les for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). HIV Med. 2011;12(6): 374-382.
28. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirap-ine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profi le. AIDS. 2001;15(18): 2407-2414. (Pubitemid 34014609)
29. Asztalos B F, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ. High-density lipoprotein subpopulation profi le and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2004;24(11): 2181-2187. (Pubitemid 39482449)
30. Asztalos BF, Collins D, Horvath KV, Bloomfi eld HE, Robins SJ, Schaefer EJ. Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profi le with cardiovascular events in the Veterans Affairs High-Density Lipo-protein Intervention Trial. Metabolism. 2008;57(1): 77-83. (Pubitemid 350234976)
31. Worm SW, Kamara DA, Reiss P, et al. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS. 2011;25(12): 1497-1500.
32. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000;86: 943-949.
33. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyc-eride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11): 1345-1361.
34. Cheng AYY, Leiter LA. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr Opin Cardiol. 2006;21(4): 400-404. (Pubitemid 44315074)
35. Patroni A, Carosi G, Castelli F, et al. Effect of highly active antiretroviral therapy (HAART) and hepatitis C co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. HIV Clin Trials. 2002;3(6): 451-461. (Pubitemid 36013553)